RET fusions are observed in about 1–2% of non-small cell lung cancers (NSCLCs) and 5–10% of papillary thyroid cancers (TCs), and RET mutations occur in approximately 70% of patients with medullary thyroid cancer (MTC) [2,3]. Here, RET is linked to medullary thyroid gland carcinoma.